Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MITO 31 – Olaparib in BRCA wild-type recurrent ovarian cancer
2024-516841-38-00Phase 2Authorised
- Sponsor
- Istituto Nazionale Tumori IRCCS Fondazione Pascale
- Start
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of olaparib in ovarian cancer, primary peritoneal cancer (PPC) and fallopian tube cancer (PFTC), sponsored by Istituto Nazionale Tumori IRCCS Fondazione Pascale. Primary endpoint: Progression Free Survival. Planned start Jan 2025; status: authorised.
02
Drugs
olaparib
03
Conditions
ovarian cancerprimary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on 2024-516841-38-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516841-38-00.